Abstract:Here, we report that all results provided the direct evidence of the pharmacokinetic drug–drug interactions (DDIs) between Schisandrin and poziotinib. When rats were pre‐administered with Schisandrin A, AUC(0−∞) and Cmax of poziotinib were obviously increased, whereas the Vz/F and CLz/F values were dramatically decreased. The results in Schisandrin B group presented similarly. Both Schisandrin A and Schisandrin B were mixed inhibitors of poziotinib in RLMs, and Schisandrin B showed stronger inhibitory activity. Molecular docking analysis demonstrated that Schisandrin A and Schisandrin B exhibited a strong binding ability towards CYP2D6 as compared to CYP3A4. Thus, particular attention should be paid when poziotinib is taken together with Schisandrins in clinical practice. Background As a pan‐HER tyrosine kinase inhibitor with a promising application prospect, poziotinib is likely to be coadministered with Schisandrins in clinical treatment due to its anticancer activities. Methods Eighteen Sprague–Dawley rats were randomly divided into three groups: Schisandrin A group and Schisandrin B group (20 mg/kg daily for 1 week), and control group (vehicle). On day 8, poziotinib (2 mg/kg) was administered by oral gavage 30 min later. An in vitro study was developed to identify the possible mechanisms of Schisandrins on poziotinib metabolism. All analytes were detected by UPLC/MS–MS, and molecular docking was performed by AutoDock Tools. Results When rats were preadministered with Schisandrin A, AUC(0−∞) and Cmax of poziotinib were obviously increased by 0.79‐ and 1.17‐fold, whereas the Vz/F and CLz/F values were dramatically decreased. The results in Schisandrin B group presented similarly. Both Schisandrin A and Schisandrin B were mixed inhibitors of poziotinib in RLMs, and Schisandrin B showed stronger inhibitory activity with IC50 values of 2.55 μM for M1 and 6.97 μM for M2. Molecular docking analysis demonstrated that Schisandrin A and Schisandrin B exhibited a strong binding ability towards CYP2D6 as compared to CYP3A4. Conclusion All results provided the direct evidence of the pharmacokinetic drug–drug interactions (DDIs) between Schisandrin and poziotinib. Thus, particular attention should be paid when poziotinib is taken together with Schisandrins in clinical practice.

Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1.

Schisandrin B--a novel inhibitor of P-glycoprotein.

Schisandrin B inhibits cell proliferation and induces apoptosis in human cholangiocarcinoma cells.

Protective effect of schisandrin B against HK-2 apoptosis induced by Cisplatin

Mechanism Study of Doxorubicin-schisandrin B Co-delivery Liposomes to Overcome Multidrug Resistance

Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.

Dibenzocyclooctadiene lignans: a class of novel inhibitors of multidrug resistance-associated protein 1.

Co-Delivery of Doxorubicin and Schisandrin B by Liposome to Overcome Multidrug Resistance

Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation

Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation

Schisandrin B enhances doxorubicin-induced apoptosis in SMMC7721 cell line

Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells.

Overcoming Multidrug-Resistance in Vitro and in Vivo Using the Novel P-glycoprotein Inhibitor 1416.

Inhibitory effect of Schisandrin on the pharmacokinetics of poziotinib in vivo and in vitro by UPLC‐MS/MS

Bioavailability and interactions of schisandrin B with 5-fluorouracil in a xenograft mouse model of colorectal cancer

Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo

Substituted Tetrahydroisoquinoline Compound B3 Inhibited P-Glycoprotein-Mediated Multidrug Resistance In-Vitro and In-Vivo

Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae